Innospec Inc (IOSP)
Official siteBASIC MATERIALS • SPECIALTY CHEMICALS • NASDAQ
Market Cap: $1.98B
Last updated: Nov 17, 2026 at 11:06 AM ET
Innospec Inc (IOSP) Earnings: Report Dates and Results
Innospec (IOSP) is expected to report earnings on Feb 15, 2027. In the quarter ended Sep 30, 2026, Innospec reported EPS of $1.29, above the $1.26 estimate. It beat the EPS estimate in 7 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
IOSP has an expected report date of Feb 15, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 3.3% below the $1.50 reported for the quarter ended Dec 31, 2025.
IOSP Earnings Call
The latest IOSP earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 40 quarters below that had an estimate, IOSP beat 34, missed 3 and matched 3. Revenue for the quarter ended Sep 30, 2026 was $473.60M, up 7.2% from $441.90M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $1.29 | $1.26 | $1.24 - $1.29 | +2.38% | Beat | +15.2% | 3 | 2 up, 0 down | Nov 3, 2026 | $473.60M |
| Jun 30, 2026 | $1.27 | $1.05 | $1.03 - $1.06 | +20.95% | Beat | +0.8% | 3 | N/A | Aug 4, 2026 | $491.40M |
| Mar 31, 2026 | $1.05 | $1.01 | $0.99 - $1.04 | +3.96% | Beat | -26.1% | 2 | 0 up, 1 down | May 7, 2026 | $453.20M |
| Dec 31, 2025 | $1.50 | $1.24 | $1.23 - $1.25 | +20.97% | Beat | +6.4% | 3 | 0 up, 2 down | Feb 17, 2026 | $455.60M |
| Sep 30, 2025 | $1.12 | $1.06 | $1.03 - $1.09 | +5.66% | Beat | -17.0% | 2 | 0 up, 1 down | Nov 4, 2025 | $441.90M |
| Jun 30, 2025 | $1.26 | $1.21 | $1.17 - $1.25 | +4.13% | Beat | -9.4% | 2 | 0 up, 1 down | Aug 5, 2025 | $439.70M |
| Mar 31, 2025 | $1.42 | $1.42 | $1.39 - $1.46 | 0.00% | In line | -18.9% | 3 | 0 up, 1 down | May 8, 2025 | $440.80M |
| Dec 31, 2024 | $1.41 | $1.36 | $1.35 - $1.37 | +3.68% | Beat | -23.4% | 3 | 0 up, 1 down | Feb 18, 2025 | $466.80M |
| Sep 30, 2024 | $1.35 | $1.35 | $1.31 - $1.39 | 0.00% | In line | -15.1% | 3 | 0 up, 0 down | Nov 5, 2024 | $443.40M |
| Jun 30, 2024 | $1.39 | $1.37 | $1.37 - $1.38 | +1.46% | Beat | +8.6% | 3 | 0 up, 0 down | Aug 6, 2024 | $435.00M |
| Mar 31, 2024 | $1.75 | $1.64 | $1.60 - $1.68 | +6.71% | Beat | +26.8% | 3 | 1 up, 0 down | May 9, 2024 | $500.20M |
| Dec 31, 2023 | $1.84 | $1.62 | $1.56 - $1.67 | +13.58% | Beat | +53.3% | 3 | 0 up, 0 down | Feb 13, 2024 | $494.70M |
| Sep 30, 2023 | $1.59 | $1.45 | $1.42 - $1.47 | +9.66% | Beat | -8.6% | 3 | 0 up, 1 down | Nov 7, 2023 | $464.10M |
| Jun 30, 2023 | $1.28 | $1.28 | $1.26 - $1.31 | 0.00% | In line | -19.0% | 3 | 0 up, 0 down | Aug 8, 2023 | $480.40M |
| Mar 31, 2023 | $1.38 | $1.17 | $1.12 - $1.26 | +17.95% | Beat | -9.8% | 3 | 1 up, 0 down | May 3, 2023 | $509.60M |
| Dec 31, 2022 | $1.20 | $1.40 | $1.33 - $1.48 | -14.29% | Miss | -7.7% | 4 | 0 up, 0 down | Feb 21, 2023 | $510.70M |
| Sep 30, 2022 | $1.74 | $1.41 | $1.36 - $1.49 | +23.40% | Beat | +51.3% | 4 | 0 up, 0 down | Nov 8, 2022 | $513.00M |
| Jun 30, 2022 | $1.58 | $1.36 | $1.30 - $1.45 | +16.18% | Beat | +21.5% | 4 | 0 up, 0 down | Aug 2, 2022 | $467.60M |
| Mar 31, 2022 | $1.53 | $1.19 | $1.15 - $1.22 | +28.57% | Beat | +44.3% | 4 | 0 up, 0 down | May 3, 2022 | $472.40M |
| Dec 31, 2021 | $1.30 | $1.07 | $1.01 - $1.07 | +21.50% | Beat | +2.4% | 2 | 0 up, 0 down | Feb 15, 2022 | $413.20M |
| Sep 30, 2021 | $1.15 | $0.96 | $0.79 - $1.20 | +19.79% | Beat | +62.0% | 3 | 1 up, 0 down | Nov 2, 2021 | $376.10M |
| Jun 30, 2021 | $1.30 | $0.89 | $0.81 - $0.98 | +46.07% | Beat | N/A | 3 | N/A | Aug 3, 2021 | $354.50M |
| Mar 31, 2021 | $1.06 | $0.99 | $0.95 - $1.02 | +7.07% | Beat | -25.4% | 2 | N/A | May 4, 2021 | $339.60M |
| Dec 31, 2020 | $1.27 | $0.77 | $0.64 - $0.78 | +64.94% | Beat | -13.6% | 2 | N/A | Feb 16, 2021 | $343.50M |
| Sep 30, 2020 | $0.71 | $0.38 | $0.29 - $0.39 | +86.84% | Beat | -49.3% | 2 | N/A | Nov 3, 2020 | $265.10M |
| Jun 30, 2020 | -$0.18 | $0.31 | N/A | -158.06% | Miss | -116.1% | 2 | N/A | Aug 4, 2020 | $244.90M |
| Mar 31, 2020 | $1.42 | $1.23 | $1.14 - $1.31 | +15.45% | Beat | +13.6% | 3 | N/A | May 5, 2020 | $339.60M |
| Dec 31, 2019 | $1.47 | $1.38 | $1.35 - $1.41 | +6.52% | Beat | -9.3% | 3 | N/A | Feb 18, 2020 | $390.70M |
| Sep 30, 2019 | $1.40 | $1.25 | $1.16 - $1.37 | +12.00% | Beat | +16.7% | 3 | N/A | Nov 5, 2019 | $371.90M |
| Jun 30, 2019 | $1.12 | $1.10 | $1.07 - $1.12 | +1.82% | Beat | +12.0% | 3 | N/A | Aug 6, 2019 | $362.40M |
| Mar 31, 2019 | $1.25 | $1.18 | $1.15 - $1.25 | +5.93% | Beat | +22.5% | 3 | N/A | May 7, 2019 | $388.30M |
| Dec 31, 2018 | $1.62 | $1.37 | $1.32 - $1.43 | +18.25% | Beat | +10.2% | 3 | N/A | Feb 19, 2019 | $395.00M |
| Sep 30, 2018 | $1.20 | $1.06 | $1.02 - $1.09 | +13.21% | Beat | +20.0% | 3 | N/A | Nov 6, 2018 | $363.10M |
| Jun 30, 2018 | $1.00 | $1.05 | $0.98 - $1.11 | -4.76% | Miss | -13.8% | 4 | N/A | Aug 7, 2018 | $358.10M |
| Mar 31, 2018 | $1.02 | $0.92 | $0.86 - $0.98 | +10.87% | Beat | +2.0% | 3 | N/A | May 8, 2018 | $360.70M |
| Dec 31, 2017 | $1.47 | $1.20 | $1.10 - $1.34 | +22.50% | Beat | +34.9% | 4 | N/A | Feb 13, 2018 | $353.80M |
| Sep 30, 2017 | $1.00 | $0.92 | $0.85 - $1.05 | +8.70% | Beat | +28.2% | 4 | N/A | Nov 7, 2017 | $332.40M |
| Jun 30, 2017 | $1.16 | $1.10 | N/A | +5.45% | Beat | +12.6% | 2 | N/A | Aug 8, 2017 | $326.30M |
| Mar 31, 2017 | $1.00 | $0.86 | N/A | +16.28% | Beat | +7.5% | N/A | N/A | May 9, 2017 | $294.30M |
| Dec 31, 2016 | $1.09 | $0.83 | N/A | +31.33% | Beat | -12.1% | N/A | N/A | Feb 14, 2017 | $237.80M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $5.30, down 10.2% from the year before. It was $3.83 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $5.30 | -10.2% |
| Dec 31, 2024 | $5.90 | -3.1% |
| Dec 31, 2023 | $6.09 | N/A |
| Dec 31, 2022 | $6.05 | +25.8% |
| Dec 31, 2021 | $4.81 | +49.4% |
| Dec 31, 2020 | $3.22 | -38.5% |
| Dec 31, 2019 | $5.24 | +8.3% |
| Dec 31, 2018 | $4.84 | +4.5% |
| Dec 31, 2017 | $4.63 | +20.9% |
| Dec 31, 2016 | $3.83 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 2,700 words across 6 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 2,660 | 6 | |
| 2026Q2 | Jun 30, 2026 | 3,728 | 7 | |
| 2026Q1 | Mar 31, 2026 | 3,299 | 7 | |
| 2025Q4 | Dec 31, 2025 | 5,072 | 7 | |
| 2025Q3 | Sep 30, 2025 | 3,022 | 6 | |
| 2025Q2 | Jun 30, 2025 | 2,818 | 6 | |
| 2024Q4 | Dec 31, 2024 | 2,387 | 5 | |
| 2024Q3 | Sep 30, 2024 | 3,351 | 7 |
2026Q3 Earnings Call
Opening remarks
David Jones General Counsel and Chief Compliance Officer Thank you. Welcome to Innospec's quarterly earnings call. This is David Jones, and I'm Innospec's General Counsel and Chief Compliance Officer. The earnings release for the quarter and this presentation are posted on the company's website. During this call, we will make forward-looking statements, which are predictions and projections about future events. These statements are based on current expectations and assumptions that are subject to risks and uncertainties that could cause actual results to differ materially from the anticipated results implied by such forward-looking statements. The risks and uncertainties are detailed in Innospec's filings with the SEC. Please see the SEC site and Innospec's site for these and related documents. In today's presentation, we've also included non-GAAP financial measures. A reconciliation to the most directly comparable GAAP financial measure is contained in the earnings release. The non-GAAP financial measures should not be considered as a substitute for those prepared in accordance with GAAP. They are included as additional items to aid investor understanding of the company's performance and anticipated impact that these items and events had on financial results. With me today from Innospec are Patrick Williams, President and Chief Executive Officer; and Ian Cleminson, Executive Vice President and Chief Financial Officer. And with that, I'll turn it over to you, Patrick.
Patrick Williams President and Chief Executive Officer Thank you, David, and welcome, everyone, to Innospec's Third Quarter 2026 Conference Call. This was a strong quarter for Innospec, with all businesses delivering sales growth and operating income improvement. Performance Chemicals sales growth and gross margin improvement drove an 84% operating income increase over last year. The North Carolina plant efficiency upgrades discussed last quarter are scheduled to be completed by year-end. These upgrades will increase capacity, productivity, and yields on a wide range of existing personal care and other products. In parallel, we will continue to focus on commercializing new products to drive further margin and operating income improvement in the coming quarters. Fuel Specialties had another strong quarter, delivering revenue and operating income growth with margins in our target range. Both volume and price/mix improved as the business has continued to manage well against raw material volatility. We expect continued strong performance and seasonal demand in the coming quarters. Oilfield Services operating income grew 40% and operating margins expanded, driven by improved volumes from our recent DRA plant expansion. Third quarter results were lower than expected due to activity delays in our Middle East legacy business, along with elevated raw material costs. We expect sequential improvement in the fourth quarter. Now I will turn the call over to Ian Cleminson, who will review our financial results in more detail. Then I will return with some concluding comments.
Frequently Asked Questions About IOSP
When is Innospec's next earnings date?
Innospec's next earnings report is expected for Feb 15, 2027.
Did IOSP beat earnings estimates last quarter?
Yes. Innospec reported EPS of $1.29 for the quarter ended Sep 30, 2026, above the $1.26 estimate, a 2.38% surprise.
What EPS do analysts expect from IOSP next quarter?
The consensus EPS estimate for Innospec for the quarter ending Dec 31, 2026 is $1.45 from 5 analysts, with estimates from $1.35 to $1.52.
How often does IOSP beat earnings estimates?
Innospec beat the EPS estimate in 7 of the last 8 quarters, with an average surprise of +7.72%.
IOSP pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors